Effects of Cyclosporine A on Pancreatic Insulin Secretion

Our primary aim is to investigate if cyclosporine A may reduce insulin secretion by 20% or more. In order to get cyclosporine A naïve patients we will perform this investigation in dialysis patients on the waiting list for a renal transplantation. In addition we will investigate if also the peripheral insulin sensitivity and endothelia function is affected by cyclosporine A treatment in these patients. Since these patients will be treated with cyclosporine A we will also measure cyclosporine pharmacokinetics at the time of investigation and repeat this investigation at the time of the first week following transplantation in order to evaluate if a pretransplant cyclosporine dose can be of value in predefining the dose to be used at the time of transplantation.

Inclusion criteria

• Renal failure patients on dialysis which is planned to receive a renal transplant

Exclusion criteria

• Age below 18 years or above 75 years
• Pregnancy
• Breast feeding mothers
• Diabetes mellitus /WHO criteria)
• Dialysis treatment less than 2 months
• Serious coronary heart disease
• Unstable angina pectoris
• Recent acute infarction (less than 3 months)
• Non-compensated heart failure
• Simultaneous treatment with glucocorticosteroids (e.g. prednisolone, dexamethasone), diltiazem, verapamil, erythromycin, clarithromycin, telithromycin, rifampicin, fluconazole, itraconazole, ketoconazole, voriconazole, indinavir, nelfinavir, ritonavir, nefazodone, bosentan, carbamazepine, St. John's worth, grapefruit.